Halozyme Therapeutics, Inc. (HALO) — Fair Value Analysis
Base-case fair value (P50): $92.78 · Current price: $83.23 · Verdict: Fairly Valued
The Verdict on HALO
HALOZYME THERAPEUTICS INC (HALO) is currently assessed as Fairly Valued based on our Monte Carlo simulations, despite trading at $83.23. Our analysis, leveraging thousands of forward-looking scenarios, indicates a median fair value (P50) of $92.78. This suggests a potential upside of +11.5% from the current market price, placing HALO squarely within a reasonable valuation range given its operational and financial health. The probabilistic modeling confirms that the current market price reflects a largely balanced risk-reward profile, aligning closely with our calculated P50 expectation.
How HALO stacks up against peers
HALOZYME THERAPEUTICS INC exhibits a strong quality tier relative to its sector peers. This robust operational and financial health underpins the $92.78 median fair value and the observed +11.5% gap from $83.23. While the company operates without a specified sector in our data, its strong fundamentals are a key factor in its valuation, differentiating it within its competitive landscape. Our Monte Carlo simulations account for this strength, incorporating it into the range of potential outcomes and ultimately contributing to the Fairly Valued verdict even with a slight implied upside.
What this means for investors
For investors, the Fairly Valued assessment suggests HALOZYME THERAPEUTICS INC (HALO) at $83.23 offers a balanced investment opportunity. The projected +11.5% towards a median fair value of $92.78 indicates that while significant undervaluation is not present, there is still room for appreciation. Investors should consider HALO's strong quality tier as a foundational element supporting this valuation. To gain deeper insights into the full distribution of potential outcomes, including bear-case and bull-case scenarios, sign up for FairCurve to see the complete probability range and track HALO's fair value as new fundamentals are released.
Frequently Asked Questions
Is HALO overvalued or undervalued right now?
HALOZYME THERAPEUTICS INC is currently assessed as Fairly Valued. Our median fair value (P50) is $92.78, compared to the current price of $83.23.
What is the bear case and bull case for HALO?
The full Monte Carlo distribution, including bear (P10) and bull (P90) price targets, as well as the probability of achieving upside scenarios, is available with a free FairCurve account. We do not provide specific dollar values here.
How does FairCurve calculate HALO's fair value?
FairCurve calculates HALO's fair value using advanced Monte Carlo simulations that model thousands of forward scenarios, incorporating various financial and operational factors to determine a probabilistic range of outcomes.
How can I track HALO's fair value as it changes?
You can add HALO to a free FairCurve watchlist to receive daily fair-value updates and instant re-valuation alerts whenever new earnings reports or significant fundamental data are released.